Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mela Sciences secondary stock offering

This article was originally published in The Gray Sheet

Executive Summary

Developer of the MelaFind melanoma diagnostic system will gross $16.5 million from a secondary stock offering of 2.2 million shares that priced at $7.50 each on June 30. Mela Sciences expects the offering to close on July 6. The proceeds will help fund MelaFind commercialization efforts, the company says. FDA's General and Plastic Surgery Devices Panel will meet Aug. 26 to review a PMA application for the device, which was filed in June 2009 (1"The Gray Sheet" June 28, 2010). Underwriters for the stock offering include Needham & Company and Leerink Swann
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT029089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel